Abstract 95P
Background
The prognosis of advanced cancer including melanoma (Mel) and NSCLC has significantly improved with ICIS, leading to the emergence of new QoL issues for patients experiencing ICI-DR. The QUALICI study aimed to provide an overview of these patients’ QoL and their experiences and expectations about QoL management.
Methods
All patients with ICI-DR, defined as ICIs started for ≥2 years without subsequent treatment, were screened within 16 French sites and randomly selected to participate in this cross-sectional study. They completed questionnaires including EQ-5D-5L, Social Difficulties Inventory (SDI) and items on care and QoL management.
Results
The 234 participating patients (117 Mel; 117 NSCLC) had a mean ICI-DR of 48.8 (±14.5) months. Of them, 74.8% initiated ICI at metastatic stage and 29,5% (22.2% Mel; 36.8% NSCLC) were still treated by ICI. Most patients (NSCLC ≥62%; Mel ≥69.7%) reported no or mild issues on the 5 EQ-5D dimensions with mean Visual Analogic Scale (VAS) score of 74.8 (±19) (Mel) and 67.0 (±19.3) (NSCLC). Total SDI scores were 5.9 (±6.6) (Mel) and 10.4 (±8.5) (NSCLC) with 25% (Mel) and 50% (NSCLC) of patients presenting difficulties (score ≥10).Patients dedicated 7.7 (Mel) and 7.5 (NSCLC) hours monthly to care and assessed the burden of care at 3.1 (Mel) and 2.5 (NSCLC) on a 0-10 VAS. Two third addressed QoL issues with healthcare professionals (HP) but 21.5% could not express them as they wished. Patients prioritized closer adverse events monitoring and HP QoL training to improve QoL management (see table). Table: 95P
Patients' expectations to improve QoL management
Useful measures to improve QoL in care | NSCLC (N=117) | Melanoma (N=117) | ||
n | % | % | ||
Closer monitoring of adverse event | 65 | 58.0 | 84 | 72.4 |
QoL training for HP development | 57 | 50.9 | 61 | 55.5 |
Better coordination of the HP team | 48 | 43.6 | 55 | 50.5 |
New care method development | 47 | 42.0 | 43 | 40.6 |
Consultation dedicated to QoL | 44 | 38.9 | 47 | 41.2 |
Longer consultation | 34 | 29.8 | 44 | 38.6 |
Psychologist involvement | 33 | 29.5 | 35 | 31.0 |
Social worker support | 33 | 29.5 | 26 | 22.6 |
Tool to facilitate QoL discussions development | 30 | 27.3 | 33 | 29.7 |
Referring to discussion groups or patient associations | 29 | 25.7 | 31 | 27.0 |
Digital tool development | 22 | 19.6 | 34 | 29.6 |
Conclusions
The majority of ICI-DR patients have no or mild QoL issues, but an important proportion, especially among lung cancer patients, presents nonetheless daily life difficulties. One in five patients do not address as they wish their QoL issues with HP. Some measures prioritized by patients could improve the situation.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Personal, Other, Family member is an employee: AstraZeneca. J. Bonastre: Financial Interests, Personal, Advisory Board, Scientific board: BMS, MSD, Janssen, Roche; Financial Interests, Institutional, Funding, Funding of the MICADO study: BMS. H. Lemasson, M. Chartier, V. Moreau-Mallet, S. Micheliza: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. N. Texier, S. Hervy, M. Coin-Bavarot: Financial Interests, Personal, Full or part-time Employment, CRO in charge of the study: Kappa Santé. C. Robert: Financial Interests, Personal, Advisory Board, Consultancy fees: BMS, Roche, Pierre Fabre, Novartis, Sanofi, MSD, Pfizer, Sun Pharma, Merck, Ultimovacs, Regeneron, Egle, Philogen, Maat Pharma; Financial Interests, Personal, Other, Steering Committee: Novartis, Regeneron, Pfizer, IO Biotech; Financial Interests, Personal, Other, IDMC: Ultimovacs; Financial Interests, Personal, Invited Speaker: Pierre Fabre, Sanofi, BMS, MSD, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract